Program

Executive Summary：
Dr. Chen graduated from Taipei Medical University and completed his neurological residency training at National Taiwan University Hospital in Taipei. Since 2012, he has served as an attending physician and movement disorder specialist in the Department of Neurology at National Taiwan University Hospital Hsinchu Branch.

Dr. Chen acquired expertise in microelectrode recording and clinical deep brain stimulation (DBS) techniques under the guidance of Dr. Chun-Hwei Tai at National Taiwan University Hospital (NTUH) and established DBS system of NTUH Hsinchu in 2015. In the field of non-invasive neurostimulation, he has conducted extensive research on transcranial magnetic stimulation (TMS) and patterned repetitive TMS (rTMS) in collaboration with Professor Ying-Zu Huang from 2016. In addition to his clinical expertise, Dr. Chen pursued a research fellowship in Professor Robert Chen’s lab at the Krembil Brain Institute, University of Toronto from 2018 to 2019. His primary research interests focus on neuromodulation and electrophysiological assessment of movement disorders, utilizing techniques such as DBS, TMS, and low-intensity transcranial focused ultrasound (TUS). Additionally, he has explored the cortical plasticity effects of TUS and developed a novel patterned repetitive TUS protocol in collaboration with Professor Robert Chen.
In 2020, Dr. Chen established his clinical neurophysiology lab, integrating electrophysiological assessments with advanced equipment, including multi-channel EMG, EEG, single/paired TMS, rTMS, evoked potentials, and gait analysis. His research encompasses a broad spectrum of movement disorders, such as parkinsonism, tremor, dystonia, functional movement disorders, and gait abnormalities.
Dr. Chen has published numerous influential articles on the principles of electrophysiology in movement disorders and human cortical physiological function. He currently serves as the Deputy Director of the Department of Neurology at National Taiwan University Hospital Hsinchu Branch.

Lecture Abstract：
Opicapone, a novel once-daily catechol-O-methyltransferase (COMT) inhibitor, plays a pivotal role in optimizing levodopa therapy for patients with Parkinson’s Disease (PD). By inhibiting peripheral levodopa metabolism, opicapone enhances its bioavailability and prolongs its clinical effect, thereby reducing motor fluctuations such as end-of-dose wearing-off. From 2016, the landmark studies (BIPARK I and BIPARK II) have demonstrated that adjunctive opicapone significantly increases ON time without troublesome dyskinesia and improves motor symptom control. Its favorable safety profile and simplified dosing regimen make it a valuable addition to individualized treatment strategies aimed at maintaining consistent dopaminergic stimulation and improving quality of life in PD patients. Meanwhile, some recent clinical evidences such as ADOPTION study, OASIS study and Epsilon study provide the new clinical role of Opicapone for the optimization of Levodopa treatment in Parkinson’s Disease patients. With new clinical options available such as Opicapone, we are able to provide the optimal treatment to get patients in early treatment as possible as we can.